Active Ingredient History

NOW
  • Now
Cycloserine was discovered simultaneously in 1954 by Eli Lilly and Merck. The drug was approved for the treatment of active pulmonary and extrapulmonary tuberculosis and marketed under the name Seromycin (among the others). Cycloserine suppresses the synthesis of bacterial wall by inhibitin two enzymes: alanine racemase and d-alanine ligase.   NCATS

  • SMILES: N[C@@H]1CONC1=O
  • InChIKey: DYDCUQKUCUHJBH-UWTATZPHSA-N
  • Mol. Mass: 102.0919
  • ALogP: -1.62
  • ChEMBL Molecule:
More Chemistry
(+)-4-amino-3-isoxazolidinone | alpha-cycloserine | cicloserina | cyclo-d-serine | cyclorin | cycloserine | (+)-cycloserine | cycloserinum | d-4-amino-3-isoxazolidinone | d-4-amino-3-isoxazolidone | dcs | d-cycloserine | d-(+)-cycloserine | farmiserina | miroseryn | orientomycin | oxamycin | pa 94 | pa-94 | (r)-4-amino-1,2-oxazolidin-3-one | (r)-4-amino-isoxazolidin-3-one | ro-1-9213 | seromycin | α-cycloserine

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue